Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135313 | 1.00 | KMT2A (0.39) | KMT2AMEN1HTTNPSR1USP2 | |
| SCHEMBL4768084 | 0.93 | MEN1 (0.37) | KMT2AMEN1HTTNPSR1USP2 | |
| SCHEMBL4140333 | 0.89 | HTT (0.40) | KMT2AMEN1HTTUSP2SMN1; SMN2 | |
| SCHEMBL4140336 | 0.89 | HTT (0.40) | KMT2AMEN1HTTUSP2SMN1; SMN2 | |
| SCHEMBL13889917 | 0.88 | LIPG (0.34) | KMT2AMEN1HTTMAPTLIPG | |
| SCHEMBL4139482 | 0.85 | LMNA (0.38) | HTTSMN1; SMN2LIPGBDKRB1LMNA | |
| SCHEMBL4139487 | 0.85 | LMNA (0.38) | HTTSMN1; SMN2LIPGBDKRB1LMNA | |
| SCHEMBL4127774 | 0.83 | KMT2A (0.45) | KMT2AMEN1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL4136559 | 0.81 | LMNA (0.38) | KMT2AMEN1MAPTLMNA | |
| SCHEMBL4136566 | 0.81 | LMNA (0.38) | KMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | KMT2A 2725/4885MEN1 2731/4885HTT 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.